Noncoding RNA-Mediated High Expression of PFKFB3 Correlates with Poor Prognosis and Tumor Immune Infiltration of Lung Adenocarcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• House CM. 中华医学会肺癌临床诊疗指南(2019版) [Chinese Medical Association guidelines for clinical diagnosis and treatment of lung cancer (2019 edi tion)]. Zhonghua Zhong Liu Za Zhi. 2020;42(4):257–287. Chinese. doi:10.3760/cma.j.cn112152-20200120-00049
   PubMedGoogle Scholar
• Shi L, Pan H, Liu Z, Xie J, Han W. Roles of PFKFB3 in cancer. Signal Transduct Target Ther. 2017;2:17044. doi:10.1038/sigtrans.2017.44
   PubMed Web of Science ®Google Scholar
• O’Neal J, Clem A, Reynolds L, et al. Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer. Breast Cancer Res Treat. 2016;160(1):29–40. doi:10.1007/s10549-016-3968-8
   PubMed Web of Science ®Google Scholar
• Han J, Meng Q, Xi Q, Wang H, Wu G. PFKFB3 was overexpressed in gastric cancer patients and promoted the proliferation and migration of g astric cancer cells. Cancer Biomark. 2017;18(3):249–256. doi:10.3233/CBM-160143
   PubMed Web of Science ®Google Scholar
• Han J, Meng Q, Xi Q, et al. Interleukin-6 stimulates aerobic glycolysis by regulating PFKFB3 at early stage of colorectal cancer. Int J Oncol. 2016;48(1):215–224. doi:10.3892/ijo.2015.3225
   PubMed Web of Science ®Google Scholar
• Gu M, Li L, Zhang Z, et al. PFKFB3 promotes proliferation, migration and angiogenesis in nasopharyngeal carcinoma. J Cancer. 2017;8(18):3887–3896. doi:10.7150/jca.19112
   PubMed Web of Science ®Google Scholar
• Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–658. doi:10.1016/j.neo.2017.05.002
   PubMed Web of Science ®Google Scholar
• Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46(D1):D956–d963. doi:10.1093/nar/gkx1090
   PubMed Web of Science ®Google Scholar
• Dweep H, Gretz N, Sticht C. miRWalk database for miRNA-target interactions. Methods Mol Biol. 2014;1182:289–305.
   PubMedGoogle Scholar
• Dweep H, Sticht C, Pandey P, Gretz N. miRWalk--database: prediction of possible miRNA binding sites by “walking” the genes of three genomes. J Biomed Inform. 2011;44(5):839–847. doi:10.1016/j.jbi.2011.05.002
   PubMed Web of Science ®Google Scholar
• Sticht C, De La Torre C, Parveen A, Gretz N. miRWalk: an online resource for prediction of microRNA binding sites. PLoS One. 2018;13(10):e0206239. doi:10.1371/journal.pone.0206239
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang X. miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res. 2020;48(D1):D127–d131. doi:10.1093/nar/gkz757
   PubMed Web of Science ®Google Scholar
• Wang X. miRDB: a microRNA target prediction and functional annotation database with a wiki interface. RNA. 2008;14(6):1012–1017. doi:10.1261/rna.965408
   PubMed Web of Science ®Google Scholar
• Wong N, Wang X. miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 2015;43(Database issue):D146–52. doi:10.1093/nar/gku1104
   PubMed Web of Science ®Google Scholar
• Yang JH, Li JH, Shao P, Zhou H, Chen YQ, Qu LH. StarBase: a database for exploring microRNA-mRNA interaction maps from Argonaute CLIP-Seq and Degrado me-Seq data. Nucleic Acids Res. 2011;39(Database issue):D202–9. doi:10.1093/nar/gkq1056
   PubMedGoogle Scholar
• Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–w102. doi:10.1093/nar/gkx247
   PubMed Web of Science ®Google Scholar
• Huang Z, Zhou JK, Peng Y, He W, Huang C. The role of long noncoding RNAs in hepatocellular carcinoma. Mol Cancer. 2020;19(1):77. doi:10.1186/s12943-020-01188-4
   PubMed Web of Science ®Google Scholar
• Xie CR, Wang F, Zhang S, et al. Long noncoding RNA HCAL facilitates the growth and metastasis of hepatocellular carcinoma by acting a s a ceRNA of LAPTM4B. Mol Ther Nucleic Acids. 2017;9:440–451. doi:10.1016/j.omtn.2017.10.018
   PubMedGoogle Scholar
• Shi L, Yang Y, Li M, et al. LncRNA IFITM4P promotes immune escape by up-regulating PD-L1 via dual mechanism in oral carcinogenesi s. Mol Ther. 2022;30:1564–1577. doi:10.1016/j.ymthe.2022.01.003
   PubMed Web of Science ®Google Scholar
• Lu L, Chen Y, Zhu Y. The molecular basis of targeting PFKFB3 as a therapeutic strategy against cancer. Oncotarget. 2017;8(37):62793–62802. doi:10.18632/oncotarget.19513
   PubMedGoogle Scholar
• Bao J, Wu Y, Wang L, Zhu Y. The role of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 in esophageal squamous cell carcin oma. Medicine. 2020;99(15):e19626. doi:10.1097/MD.0000000000019626
   PubMed Web of Science ®Google Scholar
• Li X, Liu J, Qian L, et al. Expression of PFKFB3 and Ki67 in lung adenocarcinomas and targeting PFKFB3 as a therapeutic strategy. Mol Cell Biochem. 2018;445(1–2):123–134. doi:10.1007/s11010-017-3258-8
   PubMed Web of Science ®Google Scholar
• Antao AM, Tyagi A, Kim KS, Ramakrishna S. Advances in deubiquitinating enzyme inhibition and applications in cancer therapeutics. Cancers. 2020;12(6):1579. doi:10.3390/cancers12061579
   PubMed Web of Science ®Google Scholar
• Sun T, Liu Z, Yang Q. The role of ubiquitination and deubiquitination in cancer metabolism. Mol Cancer. 2020;19(1):146. doi:10.1186/s12943-020-01262-x
   PubMed Web of Science ®Google Scholar
• Oerum S, Dégut C, Barraud P, Tisné C. m1A post-transcriptional modification in tRNAs. Biomolecules. 2017;7(1):20. doi:10.3390/biom7010020
   PubMed Web of Science ®Google Scholar
• Zhao BS, Roundtree IA, He C. Post-transcriptional gene regulation by mRNA modifications. Nat Rev Mol Cell Biol. 2017;18(1):31–42.
   PubMed Web of Science ®Google Scholar
• Deng X, Yi X, Deng J, et al. ROCK2 promotes osteosarcoma growth and metastasis by modifying PFKFB3 ubiquitination and degradation. Exp Cell Res. 2019;385(2):111689. doi:10.1016/j.yexcr.2019.111689
   PubMed Web of Science ®Google Scholar
• Zhao Z, Sun W, Guo Z, Zhang J, Yu H, Liu B. Mechanisms of lncRNA/microRNA interactions in angiogenesis. Life Sci. 2020;254:116900. doi:10.1016/j.lfs.2019.116900
   PubMed Web of Science ®Google Scholar
• Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell. 2011;146(3):353–358. doi:10.1016/j.cell.2011.07.014
   PubMed Web of Science ®Google Scholar
• Liu SH, Hsu KW, Lai YL, et al. Systematic identification of clinically relevant miRNAs for potential miRNA-based therapy in lung ade nocarcinoma. Mol Ther Nucleic Acids. 2021;25:1–10. doi:10.1016/j.omtn.2021.04.020
   PubMedGoogle Scholar
• Song J, Liu Y, Wang T, Li B, Zhang S. MiR-17-5p promotes cellular proliferation and invasiveness by targeting RUNX3 in gastric cancer. Biomed Pharmacother. 2020;128:110246. doi:10.1016/j.biopha.2020.110246
   PubMed Web of Science ®Google Scholar
• Liu J, Huang Y, Wang H, Wu D. MiR-106a-5p promotes 5-FU resistance and the metastasis of colorectal cancer by targeting TGF¦ÂR2. Int J Clin Exp Pathol. 2018;11(12):5622–5634.
   PubMed Web of Science ®Google Scholar
• Hu C, Wu J, Wang L, et al. miR-133b inhibits cell proliferation, migration, and invasion of lung adenocarcinoma by targeting CDC A8. Pathol Res Pract. 2021;223:153459. doi:10.1016/j.prp.2021.153459
   PubMed Web of Science ®Google Scholar
• Yang F, Yin Y, Wang F, et al. miR-17-5p Promotes migration of human hepatocellular carcinoma cells through the p38 mitogen-activate d protein kinase-heat shock protein 27 pathway. Hepatology. 2010;51(5):1614–1623. doi:10.1002/hep.23566
   PubMed Web of Science ®Google Scholar
• Imbert-Fernandez Y, Clem BF, O’Neal J, et al. Estradiol stimulates glucose metabolism via 6-phosphofructo-2-kinase (PFKFB3). J Biol Chem. 2014;289(13):9440–9448. doi:10.1074/jbc.M113.529990
   PubMed Web of Science ®Google Scholar
• Pezzuto A, D’Ascanio M, Ricci A, Pagliuca A, Carico E. Expression and role of p16 and GLUT1 in malignant diseases and lung cancer: a review. Thorac Cancer. 2020;11(11):3060–3070. doi:10.1111/1759-7714.13651
   PubMed Web of Science ®Google Scholar
• Ge X, Lyu P, Cao Z, et al. Overexpression of miR-206 suppresses glycolysis, proliferation and migration in breast cancer cells v ia PFKFB3 targeting. Biochem Biophys Res Commun. 2015;463(4):1115–1121. doi:10.1016/j.bbrc.2015.06.068
   PubMed Web of Science ®Google Scholar
• Wang J, Li X, Xiao Z, et al. MicroRNA-488 inhibits proliferation and glycolysis in human prostate cancer cells by regulating PFKFB 3. FEBS Open Bio. 2019;9(10):1798–1807. doi:10.1002/2211-5463.12718
   PubMed Web of Science ®Google Scholar
• Zheng WD, Zhou FL, Lin N. MicroRNA-26b inhibits osteosarcoma cell migration and invasion by down-regulating PFKFB3 expression. Genet Mol Res. 2015;14(4):16872–16879. doi:10.4238/2015.December.14.14
   PubMed Web of Science ®Google Scholar
• Shi Y, Yang D, Qin Y. Identifying prognostic lncRNAs based on a ceRNA regulatory network in laryngeal squamous cell carcino ma. BMC Cancer. 2021;21(1):705. doi:10.1186/s12885-021-08422-2
   PubMed Web of Science ®Google Scholar
• Li YH, Huang GM, Wang W, Zang HL. LncRNA HAGLR exacerbates hepatocellular carcinoma through negatively regulating miR-6785-5p. Eur Rev Med Pharmacol Sci. 2020;24(18):9353–9360. doi:10.26355/eurrev_202009_23018
   PubMed Web of Science ®Google Scholar
• Sun W, Nie W, Wang Z, Zhang H, Li Y, Fang X. Lnc HAGLR promotes colon cancer progression through sponging miR-185-5p and activating CDK4 and CDK6 in vitro and in vivo. Onco Targets Ther. 2020;13:5913–5925. doi:10.2147/OTT.S246092
   PubMed Web of Science ®Google Scholar
• Huang J, Li J, Zheng S, et al. Tumor microenvironment characterization identifies two lung adenocarcinoma subtypes with specific imm une and metabolic state. Cancer Sci. 2020;111(6):1876–1886. doi:10.1111/cas.14390
   PubMed Web of Science ®Google Scholar
• Sadeghi Rad H, Monkman J, Warkiani ME, et al. Understanding the tumor microenvironment for effective immunotherapy. Med Res Rev. 2021;41(3):1474–1498. doi:10.1002/med.21765
   PubMed Web of Science ®Google Scholar
• Jiang L, Huang J, Jiang S, et al. The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer. Cancer Immunol Immunother. 2021;70(8):2313–2321. doi:10.1007/s00262-021-02847-1
   PubMed Web of Science ®Google Scholar
• Steven A, Fisher SA, Robinson BW. Immunotherapy for lung cancer. Respirology. 2016;21(5):821–833. doi:10.1111/resp.12789
   PubMed Web of Science ®Google Scholar
• Jiang J, Wang Y, Gao Y, et al. Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review an d meta-analysis. Transl Lung Cancer Res. 2022;11(2):277–294. doi:10.21037/tlcr-22-75
   PubMed Web of Science ®Google Scholar